Ma Long, Ma Jixiang, Teng Muzhou, Li Yumin
The Second Clinical Medical College of Lanzhou University, Department of General Surgery, Lanzhou University Second Hospital, Key Laboratory of Digestive System Tumors of Gansu Province, Lanzhou, China.
Front Immunol. 2022 Mar 31;13:843106. doi: 10.3389/fimmu.2022.843106. eCollection 2022.
An increasing number of studies have shown that immunotherapy serves a significant role in treating colorectal cancer (CRC) and has become a hotspot. However, few studies used the bibliometric method to analyze this field comprehensively. This study collected 1,899 records of CRC immunotherapy from 2012 to October 31, 2021, and used CiteSpace to analyze regions, institutions, journals, authors, and keywords to predict the latest trends in CRC immunotherapy research. The United States and China, contributing more than 60% of publications, were the main drivers in this field. Sun Yat-sen University was the most active institution, while the National Cancer Institute had the highest frequency of citations. Most publications were published in the Adam E Snook was the most prolific writer, while Dung T. Le was the most commonly co-cited author. "T cell", "MMI" and "PD-1blocked" were the most widely studied aspects of CRC immunotherapy. "Immune checkpoint inhibitor", "combination therapy", "drug therapy" and "liver metastases" were current research hotspots. "Tumor microenvironment", "neutrophils", "tumor-associated macrophages", and "suppressor cell" have emerged as research hotspots in recent years. "Gut microbiota", "nanoparticle" and "tumor mutational burden" as recently emerged frontiers of research that should be closely monitored.
越来越多的研究表明,免疫疗法在治疗结直肠癌(CRC)中发挥着重要作用,并已成为一个热点。然而,很少有研究使用文献计量法对该领域进行全面分析。本研究收集了2012年至2021年10月31日期间1899条CRC免疫疗法的记录,并使用CiteSpace分析地区、机构、期刊、作者和关键词,以预测CRC免疫疗法研究的最新趋势。美国和中国的出版物贡献超过60%,是该领域的主要推动力量。中山大学是最活跃的机构,而美国国立癌症研究所的被引频次最高。大多数出版物发表在《 》上。亚当·E·斯诺克是产量最高的作者,而邓·T·勒是最常被共同引用的作者。“T细胞”“MMI”和“PD-1阻断”是CRC免疫疗法研究最广泛的方面。“免疫检查点抑制剂”“联合疗法”“药物疗法”和“肝转移”是当前的研究热点。“肿瘤微环境”“中性粒细胞”“肿瘤相关巨噬细胞”和“抑制细胞”近年来已成为研究热点。“肠道微生物群”“纳米颗粒”和“肿瘤突变负荷”是最近出现的前沿研究领域,应密切关注。